Saint-Herblain (France), April 14, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces the resumption of trading of its ordinary shares on the regulated market of Euronext in Paris, starting at 1:30 PM CEST today.

At the request of the Company, trading of Valneva’s ordinary shares was suspended on April 14, 2022 from 9:00 AM CEST to allow for the dissemination of a press release related to the Conditional Marketing Authorization granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Valneva’s inactivated whole-virus COVID-19 vaccine, VLA2001[1].

About Valneva SE

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

Media & Investor Contacts

Laëtitia Bachelot-Fontaine

VP Global Communications & European Investor Relations

M +33 (0)6 4516 7099


Joshua Drumm, Ph.D.

VP Global Investor Relations

M +001 917 815 4520

[1] Valneva Receives Conditional Marketing Authorization from UK MHRA for its Inactivated COVID-19 Vaccine